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Introduction
Children with heterozygous familial hypercholesterolemia (FH) are characterized by severely elevated LDL-cholesterol (LDL-C) levels that predispose to the early initiation of atherogenesis and premature cardiovascular disease (CVD). Although most children with this disorder are asymptomatic, they do manifest subclinical atherosclerosis such as impaired endothelial dysfunction and increased intima-media thickness (IMT) " .
Carotid IMT is considered a valid surrogate marker for atherosclerosis and therefore employed to assess atherosclerosis in children with FH. We previously showed that pravastatin therapy induced a significant regression of carotid IMT in children with FH compared to placebo .
A wealth of experimental and recently-derived clinical data suggests that lipoprotein oxidation plays an important role in atherogenesis (reviewed in j. Importantly, circulating oxidized low-density lipoproteins (OxLDL) are associated with subclinical atherosclerosis in adults ' angiographically-determined coronary artery disease , symptomatic CVD, acute coronary syndromes (ACS) and vulnerable plaques ' " ' and may also predict acute myocardial infarction (AMI) ' .
The role of circulating OxLDL in the pathogenesis of early atherosclerosis in children and the effect of statins is unknown. In the current study, we investigated the effect of pravastatin on plasma levels of several direct and indirect markers of OxLDL in a cohort of FH children, treated with pravastatin or placebo, as well as in a group of unaffected siblings.
Methods

Study population and design
We previously performed a double blind randomized placebo controlled trial to determine the 2-year efficacy and safety of pravastatin therapy in 214 children aged 8-18 years with heterozygous FH Briefly, children were eligible to participate in this study based on a documented LDL-receptor mutation or plasma levels above the 95 percentile for age and gender in a family with a history of premature CVD in conjunction with hypercholesterolemia and tendon xanthomas. Children were not eligible if they were 193 homozygous for FH or when they had a secondary cause for hypercholesterolemia Consenting children were randomly assigned to receive placebo or pravastatin 20-40 mg.
Children younger than 14 years received 20 mg pravastatin whereas those aged 14 years or older received 40 mg pravastatin daily. Children were also instructed to assume or continue a low fat diet (according to Step II AHA) and to maintain habitual physical activity during the intervention period. In addition, relevant information was assembled for 80 unaffected siblings in whom FH was definitely excluded by DNA analysis. Carotid IMT was performed as previously described ".
Lipids, lipoproteins and CRP
From the original cohort, plasma samples from 178 FH children at baseline and at 2 years and from 78 unaffected siblings at a single time point were available for OxLDL measurements. Venous blood samples were drawn after a fasting period of at least 12 hours. Plasma levels of cholesterol and triglycerides were determined by standardized enzymatic procedures (Boehringer Mannheim, Germany) and high-density lipoproteincholesterol (HDL-C) in serum was measured by an automated method (Roche Diagnostics, Basel, Switzerland). LDL-C levels were calculated using the Friedewald equation
Apolipoprotein B-100 (apoB) concentrations were assayed on a Behring nephelometer (BN 100, Behring, Frankfurt, Germany) and were calibrated on international reference samples. Lp(a) concentrations were determined using chemiluminescent ELIS A as previously described '. High sensitivity C-reactive protein (CRP) was measured by latex-enhanced nephelometry (Dade Behring Inc. Newark, DFL, USA).
Determination of OxPL/apoB Levels, Apolipoprotein B-100-Immune Complexes and Malondialdehyde (MDA)-LDL autoantibody titers Chemiluminescent ELISA was used to measure all OxLDL markers. All samples for a given assay were run in a single assay and internal controls consisting of high and low standard plasma samples were included to detect potential variations between micro titration plates. Each sample was assayed in triplicate and data are expressed as relative light units (RLU) in 100 milliseconds. The intra-assay coefficients of variation for all assays were 6-10%. IgG and IgM apoB-IC and IgG and IgM MDA-LDL (1:200 plasma dilution) autoantibodies were measured as previously described ". The content of oxidized phospholipids (OxPL) per apoB-100 particle was determined using the murine monoclonal antibody E06 (OxLDL-E06), which specifically binds to the phosphorylcholine head group of oxidized but not native phospholipids (reviewed in ' and references therein). A 1:50 dilution of plasma in phosphate-buffered saline (PBS) is added to microtiter wells coated with the monoclonal antibody MB47, which specifically binds apoB-100 particles. Under these conditions, a saturating amount of apoB-100 is added to each well and consequently an equal number of apoB-100 particles are captured in each well for all assays. The content of OxPL per apoB-100 is then determined with biotinylated E06 as previously described ". Because the amount of apoB-100 bound to each plate is essentially identical for each plasma sample ' , we arbitrarily assigned the apoB-100 RLU value in the denominator as 1 and report the OxPL/apoB values as OxPL RLU counts only.
I'M
Plasma titres of
The data for apoB-IC are presented in two ways: 1) as IC/apoB, which specifically quantifies the content of apoB-IC on each captured apoB-100 particle, and 2) as Total apoB-IC, which reflects the apoBTC content on all apoB-100 containing particles in plasma, by multiplying the plasma "IC/apoB" value by the plasma apoB-100 levels measured independently. We have previously also reported Total levels of apoB-OxPL, derived by multiplying the OxPL/apoB ratio by plasma levels of apoB-100, in patients treated with statins. Because of the difficulty in determining the exact amount of OxPL on non-Lp(a)-apoB lipoproteins vs. Lp(a), this parameter may not completely reflect the plasma levels of apoB-associated OxPL. Therefore it is not reported here pending further validation.
Statistical analysis
In the FH group, mean values between the pravastatin group and the placebo group were compared using an independent sample t-test. Chi square tests were applied for comparing distributions of dichotomous data between these groups. Differences in baseline characteristics and OxLDL markers between FH children and healthy siblings were analyzed using linear or logistic regression analyses. Since some of these children were from the same family, these analyses were performed with generalized estimating equations (GEE) in the Statistical Analyses System (SAS) procedure GENMOD to account for correlations within families. In a stepwise multivariate analysis we adjusted for potential confounders.
The effect of pravastatin on OxLDL markers, apoB-100 and Lp(a) levels was studied by comparing the difference in mean change between the pravastatin and the placebo group after 2-year treatment by analysis of covariance (ANCOVA), in which independent variables were treatment and baseline levels. Pearson and Spearmans correlations were used to summarize the relationship between OxLDL markers and Lp(a) and CRP at baseline and after 2 years.
Variables with a skewed distribution were log-transformed before the analysis. A p-level of 0.05 was considered statistically significant (two sided). Statistical analyses were done with the SAS package version 9.1 (SAS Institute Ine, Cary, NC, USA).
Results
Baseline characteristics
The baseline demographics and physical characteristics of the study group were described previously and were not significantly different between children with FH in the pravastatin group compared to the placebo group. There were no differences in those children with (N=178) and without (N=36) available blood samples for OxLDL measurements. Children with FH did not differ from unaffected siblings with regard to baseline characteristics, except for mean carotid IMT and age (Table 1) Baseline OxLDL markers, Lp(a) and lipoprotein levels in the study group and in unaffected siblings
The baseline lipid levels, apoB-100, CRP, OxPL/apoB, apoB-immune complexes and MDA-LDL autoantibodies were similar between the pravastatin and placebo groups.
However, the Lp(a) levels were borderline higher in the pravastatin group (median 196 levels 8.1 vs 7.4 mg/dl, p=0.049) ( Table 1) .
Interestingly, compared to their unaffected siblings, children with FH had significantly lower levels of OxPL/apoB (P<0.001) and IgG IC/apoB (P=0.016) but higher levels of Total IgG apoB-IC, Total IgM apoB-IC and IgM MDA-LDL autoantibodies . For OxPL/ApoB IgG and IgM IC/ApoB and autoantibodies to MDA-LDL units are in RLU, Total cholesterol, HDL-C, LDL-C, Triglycerides, Apo B-100 and Lp(a) levels are in mg/dL, hsCRP levels are given in mg/L. Carotid IMT is given in mm. Age is given in years. Values are give in means and standard deviation * given as median and interquartile ranges between brackets, t hsCRP values were available from only 16 siblings. ' p-value t-test for pravastatin group versus placebo group, p-value for logistic regression analysis adjusted for family using generalized estimating equations (GEE) in SAS procedure GENMOD for FH versus siblings. To convert Total-C ,HDL-C and LDL-C levels in mmol/L divide by 38.67. To convert Triglycerides in mmol/L divide by 88.57. Abbreviations are given in text. Table 1 ). No significance differences were present in IgM IC/apoB, IgG MDA-LDL autoantibodies or Lp(a). As shown previously, a significant difference was present for apoB-100 levels and carotid IMT at baseline between children with FH and their unaffected siblings .
Effect of pravastatin on absolute changes in OxLDL markers and Lp(a)
As previously described, TC, LDL-C and apoB-100 levels decreased significandy in the pravastatin group (p<0.001 for all) after two years, whereas no significant change occurred in the placebo group ( Table 2 ) . The absolute values of OxPL/apoB increased significantly in both the placebo (+718 ± 2674 RLU; P=0.003) and pravastatin (+2442 ± 4224 RLU; P<0.001) groups, however, it increased significandy more in the pravastatin 198 Oxidized LDJ. Table 2 ). This is consistent with previous studies showing similar increases in OxPL/apoB in response to low fat diets 17 and high-dose 1 Q atorvastaun . The Total IgG apoB-IC decreased in both the placebo (-529 ± 1313 RLU -mg/dL, p<0.001) and the pravastatin group (-1146 ± 1873 RLU.mg/dL, P<0.001), but significantly more so in the pravastatin group (-612 RLU mg/dL, 95%CI: -1090 to -133, P<0.001). The Total IgM apoB-IC only decreased in the pravastatin group (-983 ± 1540 RLU mg/dL, P<0.001) The IgG IC/apoB decreased in both the control and pravastatin groups. There were no significant differences between the pravastatin and placebo groups in IgM IC/apoB, or IgG and IgM MDA-LDL autoantibodies.
Interestingly, absolute values of Lp(a) also increased significantly in the pravastatin arm (+2.1 mg/dL ± 3.7, p<0.001) but not in the control group, as also documented previously in response to low fat diets and atorvastatin 17 ' 18 . In the entire cohort, a 199 Chapter 13 Figure 1 ).
Effect of pravastatin on relative changes in OxLDL markers and Lp(a)
As compared to placebo, pravastatin significantly increased OxPL/apoB (absolute mean transport and potentially detoxify OxPL that are generated through oxidative stress .
The reason for this increase OxPL/apoB in response to statins, which may seem paradoxical with other beneficial properties of statins, has not been fully elucidated but is clearly now a consistent finding in response to atorvastatin and pravastatin as well as in response to low fat diets, conditions where one might postulate a flux of OxPL from peripheral storage sites, such as the vessel wall. For example, the control group of this study, ingesting 32.6% total fat and 12.1% saturated fat after counselling on an AHA step II diet 4 , also had increases in OxPL/apoB and Lp(a), but lower than the pravastatin group. This is consistent with the data by Silaste et al showing an increase in OxPL/ apoB and Lp(a) by approximately 25% and 9%, respectively, after 5 weeks of medicallysupervised low fat diets. The explanations for these findings still need to be determined.
One possibility is that Lp(a) is upregulated in response to statins or low fat diet and binds OxPL that may be derived from peripheral sources, such as the vessel wall. We have recently shown that placing LDLR _/ " mice with pre-existing atherosclerosis on low fat diets results in a marked reduction in OxPL immunostaining of atherosclerotic plaques, even prior to complete lesion regression and cholesterol removal from the vessel wall, suggesting that efflux of OxPL from the vessel wall is a very early phenomenon during atherosclerosis regression ' . Additional animal data from our laboratory (Tsimikas/Witztum, unpublished observations) in several animal models with or without Lp(a), also suggests that with increase in the plasma OxPL/apoB levels following low fat diets there is concomitant reduction of OxPL immunostaining in the vessel wall, suggesting an efflux of OxPL from the vessel wall to the circulation.
In the current study, none of the OxLDL markers, Lp(a) or hs-CRP predicted change in carotid IMT. In this group whose primary risk factor was elevated LDL-C, and even after pravastatin treatment where LDL-C was still elevated at 181 mg/dl, it is likely that the changes in IMT were mainly mediated by this atherogenic lipoprotein rather than additional inflammatory components. It is not known if these OxLDL markers would predict changes in IMT with a longer follow-up period.
In summary, this study suggests that children with FH are characterized by unique changes in OxLDL markers suggesting immune activation to OxLDL. Furthermore, pravastatin treatment decreased total levels of apoB-associated immune complexes but actually increased OxPL/apoB levels, in parallel with similar increases in Lp(a) levels, which may represent a potential novel mechanism of mobilization and clearance of OxPL. Additional long-term studies in children are needed to establish whether these markers ultimately predict cardiovascular outcomes .
